What is the oral antibiotic of choice for a wound culture that grows Pseudomonas aeruginosa?

Oral Antibiotic of Choice for Pseudomonas-Positive Wound

Ciprofloxacin 750 mg orally twice daily for 14 days is the oral antibiotic of choice for wound infections caused by Pseudomonas aeruginosa. 1

Why Ciprofloxacin is the Only Reliable Oral Option

• Ciprofloxacin is the sole fluoroquinolone with reliable oral antipseudomonal activity, achieving sputum and tissue concentrations of 46–90% of serum levels due to excellent oral bioavailability that matches intravenous administration. 1, 2
• The high-dose regimen of 750 mg twice daily is mandatory—lower doses (e.g., 500 mg twice daily) provide inadequate tissue penetration and risk treatment failure with rapid resistance emergence. 1
• All other oral antibiotics lack clinically meaningful activity against Pseudomonas aeruginosa, including oral cephalosporins (cefdinir, cefuroxime, cefpodoxime), other fluoroquinolones (levofloxacin is significantly less potent; moxifloxacin and gemifloxacin have no antipseudomonal activity), and all oral penicillins. 1, 3

Treatment Duration and Monitoring

• Standard treatment duration is 14 days for documented Pseudomonas wound infections. 1
• Obtain wound culture and susceptibility testing before initiating therapy to confirm Pseudomonas aeruginosa and verify ciprofloxacin susceptibility, as resistance can develop rapidly. 1
• If no clinical improvement occurs within 3–5 days, switch to intravenous combination therapy with an antipseudomonal β-lactam (piperacillin-tazobactam, ceftazidime, cefepime, or meropenem) plus either IV ciprofloxacin or an aminoglycoside. 1, 2

When Oral Therapy is Inappropriate

Intravenous combination therapy is mandatory instead of oral ciprofloxacin in the following scenarios:

• Critically ill patients, septic shock, or ICU admission 4, 2
• Deep tissue infections such as osteomyelitis or abscess requiring surgical debridement 4
• Immunocompromised hosts including neutropenic patients or those on high-dose corticosteroids 4
• Structural bone involvement (fracture-related infection, hardware present) 4
• Recent IV antibiotic use within 90 days, which increases risk of multidrug-resistant Pseudomonas 2
• Inability to tolerate oral intake or gastrointestinal dysfunction 1

For these severe cases, use an antipseudomonal β-lactam (piperacillin-tazobactam 4.5 g IV every 6 hours, ceftazidime 2 g IV every 8 hours, cefepime 2 g IV every 8 hours, or meropenem 1 g IV every 8 hours) PLUS either ciprofloxacin 400 mg IV every 8 hours OR an aminoglycoside (tobramycin 5–7 mg/kg IV daily preferred over gentamicin due to lower nephrotoxicity). 4, 1, 2

Critical Pitfalls to Avoid

• Never use levofloxacin as first-line oral therapy for Pseudomonas—it is significantly less potent than ciprofloxacin and should only be considered as a second-line alternative at the 750 mg daily dose (never 500 mg), and even then only for non-severe infections. 1, 3
• Never extend ciprofloxacin monotherapy beyond 14 days—this promotes resistance without proven benefit; if the wound has not improved by day 14, re-evaluate with new cultures and consider IV combination therapy rather than prolonging oral treatment. 1
• Never assume lower ciprofloxacin doses (500 mg twice daily) are adequate—underdosing leads to treatment failure and rapid resistance development. 1
• Do not use ciprofloxacin monotherapy for severe infections—combination therapy with a β-lactam is required to prevent treatment failure and resistance emergence in critically ill patients or those with deep tissue involvement. 4, 2

Special Wound Management Considerations

• For fracture-related infections or implant-associated wounds, fluoroquinolones should only be started after thorough surgical debridement and when wounds are dry, as high bacterial burden promotes rapid fluoroquinolone resistance. 4
• Initial IV therapy with a β-lactam (piperacillin-tazobactam, ceftazidime, or carbapenem) for 1–2 weeks is recommended before transitioning to oral ciprofloxacin in bone and joint infections to reduce bacterial load. 4
• Obtain repeat wound cultures if clinical improvement stalls—Pseudomonas develops ciprofloxacin resistance in up to 25% of cases during monotherapy, particularly when initial MIC is >0.5 mg/L. 5, 6